According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
These approvals mark significant progress for Venus Remedies in expanding its market presence
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
These regulatory approvals signify a significant milestone for Venus Remedies Limited
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Supply readiness follows months of manufacturing to ensure timely and ample supply
Subscribe To Our Newsletter & Stay Updated
